RenewTrient Requests FDA Evidence Supporting GBL Ban
This article was originally published in The Tan Sheet
Executive Summary
GBL product maker RenewTrient Research asks FDA for proof that gamma butyrolactone presents a risk to consumers in a Feb. 11 letter to the agency. The Cocoa Beach, Fla.-based firm requests an FDA response within 30 days and, depending on the strength of the evidence against GBL, says it may return the supplement ingredient to the market. FDA has not yet responded to the letter.